ADVISORY/Oxfam Study Challenges Pfizer to Help Make Life-Saving Drugs More Readily Available to World's Poor.

Business, Health & Medical Editors/United Nations Reporters

ADVISORY...for Thursday (July 19)

--(BUSINESS WIRE)

      WHAT: A new study by Oxfam, Formula for Fairness: Patient Rights
        Before Patent Rights, analyzes Pfizer's actions and policies
        toward international trade rules and patent protections. The
        study also scrutinizes Pfizer's lobbying efforts, research &
        development focus and commitment to public health issues.

        A full report on the study will be made available at Oxfam's
        July 19th symposium before a select group of investors and
        opinion leaders. Members of the media are invited to attend
        this invitation-only event, which includes a press conference
        prior to the symposium.

      WHEN: Thursday, July 19th, 2001, 10:00 a.m.

      WHERE: The United Nations Church Center,
           777 UN Plaza, New York City

      WHY: This report is part of Oxfam's international campaign
        analyzing the human development impact of multinational
        corporations. In February, Oxfam's report on GlaxoSmithKline
        garnered tremendous public support and resulted in price
        reductions for an array of HIV/AIDS drugs.

      WHO: Oxfam is dedicated to creating lasting solutions to hunger,
        poverty and social injustice through long-term partnerships
        with poor communities around the world. As a privately funded
        organization, it can speak with conviction and integrity as it
        challenges the structural barriers that foster conflict and
        human suffering and limit people from gaining the skills,
        resources and power to become self-sufficient.

Members of the media planning to attend this invitation-only event, please RSVP to: Jennifer Iannibelli, Kennedy & Company, 914/961-2436; [e-mail]